Liposomi rivastigmina za isporuku u mozak intranazalnim putem by KARTHIK ARUMUGAM et al.
Nasal drug delivery is an attractive approach for the systemic delivery of drugs
with low oral bioavailability due to to extensive gastrointestinal breakdown or high he-
patic first-pass effect. Intranasal delivery of drugs to reach the system has been widely
studied and a number of reports is available in the literature (1). The concentration-time
profiles of drugs achieved after nasal administration are often similar to those after in-
travenous administration, with resultant rapid onset of pharmacological activity (2). In-
tranasal delivery provides a convenient route for the delivery of drugs into brain. Aro-
und 35–40 substances have been reported to reach the central nervous system after nasal
administration in experimental animals, e.g., carbamazepine (3), dopamine (4), neurotoxic
metals (5), local anaesthetics (6), carboxylic acids (7) and the nerve growth factor (8). The
olfactory region of the nasal passages has unique anatomic and physiologic attributes
that provide both extracellular and intracellular pathways into the CNS bypassing the
blood-brain barrier (9, 10). Alzheimer’s disease (AD), a progressive neurodegenerative
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The present study is mainly aimed at delivering a drug
into the brain via the intranasal route using a liposomal
formulation. For this purpose, rivastigmine, which is used
in the management of Alzheimer’s disease, was selected
as a model drug. Conventional liposomes were formula-
ted by the lipid layer hydration method using cholesterol
and soya lecithin as lipid components. The concentration
of rivastigmine in brain and plasma after intranasal lipo-
somes, free drug and per oral administration was studied
in rat models. A significantly higher level of drug was
found in the brain with intranasal liposomes of rivastig-
mine compared to the intranasal free drug and the oral
route. Intranasal liposomes had a longer half-life in the
brain than intranasally or orally administered free drug.
Delivering rivastigmine liposomes through the intrana-
sal route for the treatment of Alzheimer’s disease might
be a new approach to the management of this condition.
Keywords: rivastigmine, liposomes, intranasal administra-
tion, brain drug delivery, pharmacokinetics
* Correspondence, e-mail: ganrajesh@gmail.com
brain disorder, is the most common cause of cognitive impairment (memory, intellect,
personality) in the elderly. AD is characterized by the deposition of b amyloid protein in
the form of senile plaque deposits and formation of neurofibrillary tangles in the brain
(11).
Rivastigmine is a novel acetyl cholinesterase (AChE) inhibitor used for the treatment
of Alzheimer’s disease. Both preclinical and clinical studies have shown that rivastigmi-
ne induces substantially greater inhibition of AChE in the central nervous system (CNS)
compartment than in the periphery. Rivastigmine is rapidly and completely absorbed (>
96% of the administered dose). Peak plasma concentrations are reached in approxima-
tely 1 hour and absolute bioavailability after a 3-mg dose is about 36%. Extensive, satu-
rable first-pass metabolism leads to reduced bioavailability even though it is completely
absorbed. Rivastigmine is rapidly and extensively metabolized, primarily via cholines-
terase-mediated hydrolysis, to the decarbamylated metabolite (12).
Carrier systems play an important role in drug delivery into the system by over-
coming limitations of the nasal route such as ciliary clearance, breakdown by nasal pep-
tidase enzyme, etc. Liposomes are one of the carrier systems, that offers advantages such
as better absorption and better drug retention in nasal mucosa (13, 14). Drugs like nife-
dipine and vaccines have been studied for incorporation into liposome formulations for
systemic delivery (15, 16). Intranasal route of drug delivery is a promising route of drug
delivery into the brain, which might be augmented using suitable carrier systems like
liposomes, thereby enhancing CNS penetration of drugs and also delivering drugs in a
sustained manner.
The aim of this study was to deliver rivastigmine into brain by administering it
through the intranasal route using a novel carrier system such as liposome. The objec-
tives included formulation of rivastigmine liposomes and its in vitro and in vivo evalua-
tions, which included pharmacokinetics of rivastigmine in rat plasma and brain.
EXPERIMENTAL
Rivastigmine and venlafaxine were kindly donated by Torrent Pharmaceuticals, In-
dia. Soya lecithin (type II) and cholesterol were from Sigma Chemicals, USA. Dichloro-
methane, diethyl ether were from Ranbaxy Fine Chemicals, India. Methanol HPLC
grade, acetonitrile HPLC grade, sodium dihydrogen phosphate and chloroform HPLC
grade were from Merck, India. Orthophosphoric acid was from SD Fine Chemicals Ltd.,
India. All other reagents and chemicals used were of analytical grade.
Preparation of rivastigmine liposomes
In the present study, multi lamellar liposomes were prepared by the lipid layer hy-
dration method (20). Soya lecithin and cholesterol were weighed (4:1 molar ratio) and
dissolved in chloroform and transferred to a 100-mL round bottom flask. The flask was
attached to a rotary evaporator (Serwell Instruments, India) immersed in a 45.0 °C water
bath and rotated under vacuum. This process continued until all the liquid evaporated
and a dry thin lipid film was deposited on the walls of the flask. The flask was left in a
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vacuum desiccator overnight to ensure complete removal of residual solvent. Then, the
drug was dissolved in phosphate buffer saline (PBS) pH 7.4 added to the dried film and
vortexed for 10 minutes. Liposome suspension was then subjected to three freezing-tha-
wing cycles, freezing at –80 °C and then thawing in a water bath at 30 °C. The liposomal
suspension was stored at 4 °C until analysis.
Evaluation of liposomes
Encapsulation efficiency. – Drug encapsulation efficiency was determined by the
minicolumn centrifugation method (17). Disposable syringes (1 mL) were first plugged
with cotton and packed with hydrated Sephadex G-25M gel (1%, m/V). Sephadex G-25
was previously soaked in 0.9% (V/V) saline for 4 h. These syringes were placed in plas-
tic centrifugal tubes and the whole assembly was centrifuged at 6700´g for 15 min to
make the bed dry. To this dried bed, 500 mL of liposomal suspension was added and the
assembly was centrifuged at 600´g for 15 min. The encapsulated drug was separated ba-
sed on the molecular size. This process was repeated three times using fresh syringes
packed with gel each time to ensure complete removal of non-entrapped free drug. The
concentration of the encapsulated drug was estimated by the HPLC method.
The HPLC system consisted of a Shimadzu LC-10 ADVP system with LC1OAT-VP
pump and SPD M-10AVP photo diode array detector. Mobile phase consisted of 20
mmol L–1 phosphate buffer pH 3.0 and acetonitrile (75:25 %, V/V) at a flow rate of 1 mL
min–1. The stationary phase was Kromasil C8 (250 ´ 4.6 mm, 5 mm). The detection wave-
length was kept at 210 nm.
Morphological studies
Optical microscopy. – Formation of multilamellar vesicles was confirmed by examin-
ing the liposomal suspension under an optical microscope with the magnification power
of 40 x (Olympus CX41, Philippines).
Scanning electron microscopy. – The surface morphology of liposomes was studied
using scanning electron microscopy (Hitachi model S-3000H, Japan). The resolution of
3.5 nm was used with a secondary electron image display. The liposomes were coated
with gold-palladium alloy (150–250 Å) using a sputter coater. The coater was operated
at 2.2 kV, 20 mV, 13.33 Pa (argon) for 90 seconds. Accelerating voltage of 15 kV and mag-
nification of 200 x were used to scan the liposomes.
Particle size measurement
The particle size of liposomes was measured using a particle size analyzer (Malvern
Mastersizer 2000, UK). The liposome size distribution profile was determined by light
scattering based on the laser diffraction method. Liposomes were immersed in oil me-
dium before measurement. All measurements were carried out at 25 ± 1 °C by scattering
light at 90 °C.
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In vitro release studies
The in vitro release of rivastigmine from the liposomal formulation was determined
by the dialysis sac method (Sigma membrane, Mr cut off 10,000). Simulated nasal fluid
(SNF) was used as medium for in vitro release studies. The pH of solution was main-
tained within the pH range of 6.2–6.8. About 1 mL of liposomal suspension was placed
in the dialysis sac, which was immersed in 100 mL of SNF maintained at 37 °C and
stirred with a magnetic stirrer. Samples of 1 mL were drawn at predetermined time in-
tervals of 5, 15, 25, 35, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes. In order to
maintain sink conditions, an equal volume of SNF was replaced. The samples were ana-
lyzed by the HPLC method (as mentioned under encapsulation efficiency) to determine
the concentration. This experiment was done in triplicate and the average percentage re-
lease was calculated.
Stability studies
The stability of rivastigmine liposomes was assessed by subjecting liposomal sus-
pensions to different temperature conditions, i.e., 4 °C (refrigerator) and accelerated con-
ditions 25 ± 2 °C, 60 ± 5 % relative humidity (RH) (thermo stability chamber) for a pe-
riod of 3 months. Liposomal suspensions were kept in sealed ampoules (2-mL capacity)
after flushing with nitrogen. Samples were withdrawn periodically and analyzed by
HPLC to determine the drug content.
Bioanalytical HPLC method
Chromatographic separation was achieved with a reverse phase Grace Vydac mo-
nomeric column C18 (4.6 × 250 mm) 5 mm and the mobile phase consisted of 20 mmol L–1
phosphate buffer pH 3.0 and acetonitrile (75 : 25) with flow rate of 1 mL min–1. The eff-
luents were measured by fluorimetric detection with excitation and emission wavelength
at 220 and 293 nm, respectively.
Extraction of rivastigmine from the plasma and brain sample was carried out using
the liquid-liquid extraction (LLE) technique. 100 mL of rat plasma or brain sample was
mixed with 20 mL of the internal standard (venlafaxine) working stock solution (50 mg
mL–1) and was vortexed for 60 s. Then 2 mL of dichloromethane was added and centri-
fuged at 1677´g for 5 min. Clear 1.8 mL of organic layer was separated and evaporated
in a turbo vap LV Evaporator (Zymark, USA) at 40 °C under a nitrogen stream. The dri-
ed residue was then reconstituted with 200 mL of mobile phase and 40 mL was subjected
for HPLC analysis. The analysis was carried out on a Shimadzu LC-10 series chromato-
graphic system (Shimadzu) equipped with a LC10AT-VP pump and RF-10AXL fluores-
cence detector.
In vivo studies
Plasma pharmacokinetics study. – Animal studies were carried out using male Wistar
rats after obtaining the Institutional Animal Ethics Committee Approval. The animals
were maintained under controlled conditions with temperature of 25 °C and RH of 45%
in polypropylene cages filled with sterile paddy husk. They were fed a balanced diet
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and water ad libitum. The rats were divided into three groups, each containing six rats
weighing about 200–250 g. Animals were fasted overnight before the study. Group I was
administered oral rivastigmine and group II received rivastigmine free drug intrana-
sally. Animals were kept in the supine position for 2 minutes after administration of the
nasal dose. Group III was administered intranasal rivastigmine liposomes. All three gro-
ups reccived 1.08 mg kg–1 b.m. rivastigmine. About 300-mL blood samples were collec-
ted into the EDTA-added centrifuge tubes at predetermined time intervals of 5, 10, 15,
30, 45, 60, 120, 180, 300, 480 and 720 minutes from the retro orbital vein by using hepari-
nized capillary tubes. Blood samples were centrifuged at 1700×g (Remi cooling centri-
fuge, India) for 5 minutes at 0 °C. The plasma was separated and stored at –20 °C. The
rivastigmine concentration in plasma was determined by HPLC.
Brain pharmacokinetics study
The rats were divided into three groups. Group I had 27 animals and other groups
had 18 animals each. Group I was administered rivastigmine throught the oral route.
Group II received rivastigmine intranasally, and the third group was administered the
rivastigmine liposomes through the intranasal route. All three groups were administra-
ced 1.08 mg kg–1 b.m. rivastigmine. Three animals per time interval were dissected at 15,
30, 45, 60, 120 and 180 minutes for all three groups. For group III, three additional time
points (240, 360 and 720 minutes) were included. After administration of the dose, the
animals were sacrificed by the cervical necrosis method and then the brain was removed
and washed twice with saline, which was then wiped with a soft tissue and weighed
and stored in freezer until analysis. The brain tissue was homogenized with phosphate
buffer saline (pH 7.4) under cool conditions and samples were extracted and analyzed
by HPLC.
Pharmacokinetic parameters
Pharmacokinetic parameters were evaluated using PK solution 2.0 software (non-
-compartmental modeling) and statistical evaluation was carried out using the Graph
Pad Prism software package (Version 4.03). Pharmacokinetic parameters such as cmax,
tmax, kel,, AUC0 to a, and t½ were calculated for all groups.
RESULTS AND DISCUSSION
Encapsulation efficiency of the developed formulation was found to be 80.0 ± 5.0%.
The morphological study with optical microscopy and scanning electron microscopy
(Fig. 1) showed that the developed liposomes had a smooth surface and were spherical
in shape with multilamellar vesicles. The particle size of liposomes (> 90%) was found to
be 10.0 ± 2.8 mm (Table I).
Cumulative drug release was found to be 56.0 ± 2.3% after 6 hours (Fig. 2). Release
studies showed that there was a burst release initially and then release followed a log
phase. The plateau observed after one hour might be due to equilibration of drug con-
centration between the donor and receptor compartments.
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Fig. 1. Scanning electron microscopy of
rivastigmine liposomes.
Table I. Characterization of rivastigmine liposomes
Parameter Means ± SDa
Particle size (mm) 10.0 ± 2.8
Encapsulation efficiency (%) 80.0 ± 5.0
Surface morphology Smooth
Shape Spherical
Drug release after 6 h (%) 56.0 ± 2.3
Stability after 3 months at 4 °C (%) 95.1 ± 3.6
Stability after 3 months at 25 °C/60% RH (%) 85.8 ± 2.4



























Fig. 2. In vitro release of rivastigmine from liposomes (mean ± SD, n = 3).
All stability studies were carried out in glass bottles (type II USP glass containers)
(18) made of treated soda lime glass. Stability studies were carried out at 4 °C and 25
°C/60% RH for a period of 3 months and the percentage drug content is shown Table I.
The physical stability of liposomes showed that none of the samples were agglomerated.
The percentage drug content at the end of three months was found to be 95.2 ± 3.6 and
85.8 ± 2.4 at 4 °C and 25 °C, respectively. The results indicated that the developed lipo-
some formulation should be stored at 4 °C.
HPLC validation
The developed in-house method was very sensitive to quantify rivastigmine in
plasma and brain in very low concentrations (10 ng mL–1). The method was selective for
the analyte and there was no interference from endogenous compounds at the retention
time of rivastigmine and internal standard. The typical chromatogram of rivastigmine
and internal standard is shown in Fig. 3. The calibration line concentration range was
between 10–3000 ng mL–1 (R2 = 0.9998). The mean extraction recovery of rivastigmine
from plasma and brain tissue homogenate was 80.8 ± 1.1% and 85.0 ± 1.2%, respectively.
The intra- and inter-day precision (n = 6) ranged from 2.3 to 5.7%. The intra- and inter-
-day accuracy (n = 6) showed that the developed method was accurate and the % bias
was 7.0 and 6.0%, respectively.
In vivo studies
Rivastigmine concentration in plasma after oral and nasal administration as free drug
and after intranasal administration of liposomal preparation is given in Table II. When
AUCs of these groups were compared, the intranasal liposome group had five-fold
higher AUC (36.13 ± 1.87 mg min mL–1) when compared to orally administered free drug
(6.58 ± 0.26 mg min mL–1) and an almost three-fold higher value compared free drug ad-
ministrated intransally (12.99 ± 0.87 mg min mL–1).
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Fig. 3. Typical chromatogram of rivastigmine and internal standard.
When cmax and tmax were compared, nasally administered free drug reached its
peak within 5 minutes (cmax = 0.35 mg mL–1) whereas the intranasal liposomal formula-
tion attained its peak in 45 minutes with a cmax of 0.60 mg mL–1 (Fig. 4a).
Intranasal liposome group was compared with the oral free drug group and it was
found that liposomal formulation had 10 times higher cmax. Higher systemic AUC was
observed with intranasal rivastigmine liposomes compared to free drug. Intranasal free
drug attained earlier peak than liposomal drug. This phenomenon could be explained
by the fact that free drug reached the systemic circulation rapidly via the nasal route
whereas liposomal drug might have been accumulated into the nasal mucosa and re-
leased slowly into the circulation delaying its tmax but almost doubling its cmax compa-
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Table II. Plasma pharmacokinetic parameters of rivastigmine following various routes of administrationa
Parameter Free drug (oral) Free drug (intranasal) Liposomes intranasal
AUC(0–)
(mg min mL–1)
6.58 ± 0.26b 12.99 ± 0.87d 36.13 ± 1.87b,d
cmax (mg mL–1) 0.06 ± 0.02b 0.35 ± 0.05d 0.60 ± 0.04b,d
tmax (min) 15 ± 4b 5 ± 3d 30 ± 9b,d
t1/2(min) 128.57 ± 21.69c 63.78 ± 16.23d 109.28 ± 16.92b,d
a Mean ± SD, n = 6.
b Significant difference between free drug oral vs. intranasal liposomes, p < 0.01 (99% CI).
c Significant difference between free drug oral vs. intranasal liposomes, p < 0.05 (95% CI).





















































Fig. 4. Rivastigmine time profiles after various routes of administration in: a) plasma (mean ± SD,
n = 6); b) brain (mean ± SD, n = 3); free drug oral (  ), free drug intranasal (  ), liposomes
intranasal (  ).
red to free drug. A similar result was reported by Barakat et al. (3), who studied absorp-
tion of carbamazepine after intranasal administration.
When rivastigmine concentrations in the brain were studied after oral and intrana-
sal administrations, intranasal administration attained 5.6 times higher concentration in
the brain than oral administration. Intranasal free drug attained tmax within 15 min whe-
reas intranasal liposomes reached tmax in 60 min. Liposomal formulation had a longer
half-life (173 min) than oral administration (118 min) (Table III, Fig. 4b).
Lipophilicity, molecular mass, route of administration and P-glycoprotein efflux are
the factors considered to determine the transfer of drugs across blood brain barrier (19).
This study is also in conformity with the factors stated above, since the liposomal for-
mulation achieved better absorption into the brain following intranasal administration
compared to the free drug. This might also be due to direct transfer of the drug from na-
sal mucosa to the brain via the olfactory route. A number of authors have worked in this
area of the nasal-brain pathway and have consistently shown that intranasal delivery is
a promising route for delivery of drugs into the CNS system (20).
CONCLUSIONS
Intranasal administration of rivastigmine liposomes significantly increased the ex-
posure and resulted in its higher concentration in the brain. Sustained release of rivastig-
mine from the liposomes may be used to reduce the frequency of administration and in-
crease patient compliance. Demonstration of direct delivery of rivastigmine into the
brain in significant quantities might help further research in this area and studies of its
implications for the clinical practice.
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Table III. Pharmacokinetic parameters of rivastigmine in brain following various routes of administrationa
Parameter Free drug (oral) Free drug (intranasal) Liposomes (intranasal)
AUC(0–) (mg min mL–1) 20.72 ± 1.25b 126.37 ± 11.76d 408.18 ± 22.47b,d
cmax (mg mL–1) 0.17 ± 0.18b 0.33 ± 0.29d 0.98 ± 0.74b,d
tmax (min) 30 ± 6c 15 ± 4d 60 ± 19c,d
t1/2 (min) 118 ± 15b 115 ± 16d 173 ± 14b,d
a Mean ± SD, n = 3.
b Significant difference between free drug oral vs. intranasal liposomes, p < 0.01 (99% CI).
c Significant difference between free drug oral vs. intranasal liposomes, p < 0.05 (95% CI).
d Significant difference between free drug intranasal vs. intranasal liposomes, p < 0.01 (99% CI).
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S A @ E T A K
Liposomi rivastigmina za isporuku u mozak intranazalnim putem
KARTHIK ARUMUGAM, GANESA SUNDARARAJAN SUBRAMANIAN, SURULIVEL RAJAN MALLAYASAMY,
RANJITH KUMAR AVERINENI, MEKA SREENIVASA REDDY AND i NAYANABHIRAMA UDUPA
Glavni cilj rada je razvoj liposoma za intranazalnu primjenu za isporuku lijeka u
mozak. U tu svrhu izabran je rivastigmin kao modelni lijek koji se upotrebljava u terapiji
Alzheimerove bolesti. Liposomi su pripravljeni metodom hidratacije lipidnog sloja kori-
ste}i kolesterol i lecitin iz soje kao lipidne komponente. Pra}ena je koncentracija rivastig-
mina u mozgu i plazmi nakon intranazalne i peroralne primjene liposoma i slobodnog
lijeka. S intranazalnim liposomima rivastigmina postignuta je zna~ajno ve}a koncentra-
cija lijeka u mozgu. Osim toga intranazalni liposomi imaju dulje vrijeme polu`ivota u
mozgu. Intranazalna primjena liposoma rivastigmina mogla bi predstavljati novi pris-
tup terapiji Alzheimerove bolesti.
Klju~ne rije~i: rivastigmin, liposomi, intranazalna primjena, isporuka lijeka u mozak, farmakokinetika
Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal,
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